[go: up one dir, main page]

WO1998031335A3 - Utilisation d'un antagoniste et/ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue - Google Patents

Utilisation d'un antagoniste et/ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue Download PDF

Info

Publication number
WO1998031335A3
WO1998031335A3 PCT/FR1998/000062 FR9800062W WO9831335A3 WO 1998031335 A3 WO1998031335 A3 WO 1998031335A3 FR 9800062 W FR9800062 W FR 9800062W WO 9831335 A3 WO9831335 A3 WO 9831335A3
Authority
WO
WIPO (PCT)
Prior art keywords
cosmetic
composition
receptor
sensitive skin
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1998/000062
Other languages
English (en)
Other versions
WO1998031335A2 (fr
Inventor
Lionel Breton
Isabelle Nonotte
Lacharriere Olivier De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to JP53331398A priority Critical patent/JP2001511782A/ja
Priority to EP98902077A priority patent/EP1014928A2/fr
Publication of WO1998031335A2 publication Critical patent/WO1998031335A2/fr
Anticipated expiration legal-status Critical
Publication of WO1998031335A3 publication Critical patent/WO1998031335A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à l'utilisation d'un antagoniste de la sérotonine spécifique du récepteur 5HT2 ou d'un agoniste de la sérotonine spécifique du récepteur 5HT1D dans une composition cosmétique ou pour la préparation d'une composition dermatologique pour traiter les peaux sensibles. Elle se rapporte en particulier à l'utilisation d'un antagoniste de la sérotonine spécifique du récepteur 5HT2 ou d'un agoniste de la sérotonine spécifique du récepteur 5HT1D humain pour prévenir et/ou lutter contre les irritations cutanées et/ou les dartres et/ou les érythèmes et/ou les sensations dysesthésiques et/ou les sensations d'échauffement et/ou les prurits de la peau dans ou pour la préparation d'une composition cosmétique ou dermatologique.
PCT/FR1998/000062 1997-01-16 1998-01-14 Utilisation d'un antagoniste et/ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue Ceased WO1998031335A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP53331398A JP2001511782A (ja) 1997-01-16 1998-01-14 敏感肌のための化粧品または皮膚科用組成物における５ｈｔ▲下２▼及び５ｈｔ▲下１ｄ▼レセプターそれぞれに特異的なセロトニンアンタゴニストまたはアゴニストの使用
EP98902077A EP1014928A2 (fr) 1997-01-16 1998-01-14 Utilisation d'un antagoniste et/ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5htid dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR97/00412 1997-01-16
FR9700412A FR2758263B1 (fr) 1997-01-16 1997-01-16 Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue

Publications (2)

Publication Number Publication Date
WO1998031335A2 WO1998031335A2 (fr) 1998-07-23
WO1998031335A3 true WO1998031335A3 (fr) 1999-09-10

Family

ID=9502657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1998/000062 Ceased WO1998031335A2 (fr) 1997-01-16 1998-01-14 Utilisation d'un antagoniste et/ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue

Country Status (4)

Country Link
EP (1) EP1014928A2 (fr)
JP (1) JP2001511782A (fr)
FR (1) FR2758263B1 (fr)
WO (1) WO1998031335A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866567A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee
WO2005120456A2 (fr) * 2004-06-09 2005-12-22 Pfizer Limited Nouvelle formulation de l'eletriptan
ES2317138T3 (es) 2004-11-22 2009-04-16 Hisamitsu Pharmaceutical Co., Inc. Parche transdermico que comprende un agente de diminucion del punto de fusion.
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
EP3484462B1 (fr) * 2016-07-15 2022-12-14 Institut Pasteur Agent stimulant le récepteur de la 5-hydroxytryptamine 1b pour la réparation de la peau et/ou des cheveux.
SE2250051A1 (en) * 2022-01-20 2023-07-21 Amidea Sweden Ab New pharmaceutical composition and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335442A2 (fr) * 1988-03-28 1989-10-04 Janssen Pharmaceutica N.V. Agents de conservation ou rénovation du bon état de la peau
WO1991002527A1 (fr) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Procede et composition de traitement d'hypersensibilite cutanee, oculaire et des muqueuses, d'etats inflammatoires et hyperproliferatifs en utilisant des preparations topiques d'antagonistes de serotonine
ZA906583B (en) * 1989-08-21 1991-09-25 Beth Israel Hospital Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammatory,and hyperproliferative conditions using topical preparations of nifedipine
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
EP0716850A1 (fr) * 1994-12-19 1996-06-19 L'oreal Utilisation d'un dérivé de l'éthylène diamine dans une composition cosmétique ou dermatologique et composition contenant notamment un produit à effet secondaire irritant
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
JPH08217695A (ja) * 1995-02-10 1996-08-27 Pola Chem Ind Inc 皮膚外用剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335442A2 (fr) * 1988-03-28 1989-10-04 Janssen Pharmaceutica N.V. Agents de conservation ou rénovation du bon état de la peau
WO1991002527A1 (fr) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Procede et composition de traitement d'hypersensibilite cutanee, oculaire et des muqueuses, d'etats inflammatoires et hyperproliferatifs en utilisant des preparations topiques d'antagonistes de serotonine
ZA906583B (en) * 1989-08-21 1991-09-25 Beth Israel Hospital Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammatory,and hyperproliferative conditions using topical preparations of nifedipine
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
EP0716850A1 (fr) * 1994-12-19 1996-06-19 L'oreal Utilisation d'un dérivé de l'éthylène diamine dans une composition cosmétique ou dermatologique et composition contenant notamment un produit à effet secondaire irritant
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
JPH08217695A (ja) * 1995-02-10 1996-08-27 Pola Chem Ind Inc 皮膚外用剤

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 95, Philadelphia, PA, US; abstract no. 243985, H. HASHIMOTO: "Effects of KB-2796 on plasma extravasation following antidromic trigeminal stimulation in the rat" *
BIOLOGICAL ABSTRACTS, vol. 97, Philadelphia, PA, US; abstract no. 444074, M. HASHIMOTO: "Effects of KB-2796 on plasma extravasation following antidromic trigeminal stimulation in the rat" XP002050785 *
CHEMICAL ABSTRACTS, vol. 116, no. 15, 13 April 1992, Columbus, Ohio, US; abstract no. 143854, SHARPE, RICHARD J. ET AL: "Treatment of cutaneous hypersensitivity with topical calcium channel blockers" XP002044443 *
CHEMICAL ABSTRACTS, vol. 125, no. 24, 9 December 1996, Columbus, Ohio, US; abstract no. 309031, ENDO, MASAYUKI ET AL: "Antiitching compositions containing amino acids and other ingredients for atopic dermatitis" XP002044442 *
JAPANESE JOURNAL OF PHARMACOLOGY, vol. 67, no. 1, 1995, XP002050784 *
K. GRADIN: "Interaction between substance P and serotonergic mechanisms at preganglionic sympathetic nerves in thoracic spinal cord", ACTA PHYSIOL SCAND, vol. 138, 1990, pages 101 - 102, XP002077481 *
R. SAKAKIBARA: "Treatment of primary erythromelalgia with cyproheptadine", JOURNAL OF THE AUTONOMIC NERVOUS SYSTEM, vol. 58, 1996, pages 121 - 122, XP002044441 *
RESEARCH COMMUNICATION IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, vol. 1, 1997, pages 79 - 94 *

Also Published As

Publication number Publication date
JP2001511782A (ja) 2001-08-14
FR2758263B1 (fr) 1999-12-17
EP1014928A2 (fr) 2000-07-05
WO1998031335A2 (fr) 1998-07-23
FR2758263A1 (fr) 1998-07-17

Similar Documents

Publication Publication Date Title
HUP9600162A2 (en) Use of an antagonist of cgrp in cosmetic, pharmaceutical or dermatological compositions and the cosmetic compositions
AU2666901A (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
AU7604798A (en) Non-steroidal agonist compounds and their use in male hormone therapy
GR980300033T1 (en) Compositions for the treatment of dermatological disorders and methods for their use
HUP0004170A3 (en) Methods and materials for treating and preventing inflammation ofmucosal tissue
PT869126E (pt) Derivados de ditiolano, sua preparacao e seus efeitos terapeuticos
AU3683800A (en) Device for the therapeutic and cosmetic photo-processing of biological tissues and method for using the same
AU4861196A (en) Formulations and methods for reducing skin irritation
IL127943A0 (en) Pharmaceutical and cosmetic composition for the treatment of skin disorders
AU8905098A (en) Skin care compositions and use
AU694702B2 (en) W/O emulsion with a high electrolyte content, and its use in dermo-cosmetics, in particular for treating phenomena of irritation and/or of sensitive skin
ZA989556B (en) Benzoxazine derivatives their preparation and their therapeutic application
AU1164601A (en) Therapeutic use and formulation
AU6460299A (en) Radiation device for therapeutic and cosmetic purposes
HUP0101528A3 (en) The treatment of fertility disorders use of lhrh antagonists and antioestrogens in
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
WO1998031335A3 (fr) Utilisation d'un antagoniste et/ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
HU9802886D0 (en) Substituted heterocyclic benzocycloalkenes and their use as analgetic active ingredients
ZA9810558B (en) Imidazole derivatives their preparation and their therapeutic application
AU9064191A (en) Use of angiotensin ii receptor antagonists in the treatment of atheroma
IL123156A0 (en) Benzenesulphonamide derivatives their preparation and their application in therapy
AU5704998A (en) Protective agents for skin and hair
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
AU2351699A (en) The human calcium-sensing receptor in the detection and treatment of cancer
AU1801297A (en) Spiro-ketal derivatives and their use as therapeutic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998902077

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 09331852

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998902077

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998902077

Country of ref document: EP